Business Description
Processa Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US74275C1062
Description
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 31.17 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 38.9 | |||||
| 3-Year EPS without NRI Growth Rate | 33.7 | |||||
| 3-Year FCF Growth Rate | 9.8 | |||||
| 3-Year Book Growth Rate | -50.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.01 | |||||
| 9-Day RSI | 56.41 | |||||
| 14-Day RSI | 52.01 | |||||
| 6-1 Month Momentum % | -66.37 | |||||
| 12-1 Month Momentum % | -79.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.7 | |||||
| Quick Ratio | 7.7 | |||||
| Cash Ratio | 6.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.9 | |||||
| Shareholder Yield % | -92.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -142.85 | |||||
| ROA % | -123.54 | |||||
| ROIC % | -1862.32 | |||||
| ROC (Joel Greenblatt) % | -1929.44 | |||||
| ROCE % | -145.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.55 | |||||
| Price-to-Tangible-Book | 0.55 | |||||
| EV-to-EBIT | -0.21 | |||||
| EV-to-Forward-EBIT | -0.14 | |||||
| EV-to-EBITDA | -0.21 | |||||
| EV-to-FCF | -0.3 | |||||
| Price-to-Net-Current-Asset-Value | 0.57 | |||||
| Price-to-Net-Cash | 0.71 | |||||
| Earnings Yield (Greenblatt) % | -476.19 | |||||
| FCF Yield % | -131.3 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers